- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled - WARREN,…
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will…
ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment…
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses…
NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage…
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of…
MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on…
WALTHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…
Data demonstrates the potential of ‘1805 to reset the immune system through its unique mechanism of action across various autoimmune…
Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company…